PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35614973-7	2022	Previous work has identified two DAT pharmacological chaperones with moderate potency and efficacy: bupropion and ibogaine.	Ibogaine	114-122	solute carrier family 6 member 3	Homo sapiens	33-36	
29086036-6	2018	Ibogaine and its metabolite noribogaine also rescue several disease-relevant mutants of DAT.	Ibogaine	0-8	solute carrier family 6 member 3	Homo sapiens	88-91	
33860180-3	2021	Ibogaine and its active metabolite noribogaine correct folding defects in the dopamine transporter (DAT), but they rescue only a very limited number of folding-deficient DAT mutant proteins, which give rise to infantile Parkinsonism and dystonia.	Ibogaine	0-8	solute carrier family 6 member 3	Homo sapiens	78-98	
33860180-3	2021	Ibogaine and its active metabolite noribogaine correct folding defects in the dopamine transporter (DAT), but they rescue only a very limited number of folding-deficient DAT mutant proteins, which give rise to infantile Parkinsonism and dystonia.	Ibogaine	0-8	solute carrier family 6 member 3	Homo sapiens	100-103	
27555326-5	2016	Bupropion and ibogaine increased wild type DAT protein levels and also promoted maturation of the endoplasmic reticulum (ER)-retained DAT mutant K590A.	Ibogaine	14-22	solute carrier family 6 member 3	Homo sapiens	43-46	
27555326-4	2016	After screening a set of known DAT ligands for their ability to increase DAT surface expression, we found that bupropion and ibogaine increased DAT surface expression, whereas others, including cocaine and methylphenidate, had no effect.	Ibogaine	125-133	solute carrier family 6 member 3	Homo sapiens	31-34	
27555326-4	2016	After screening a set of known DAT ligands for their ability to increase DAT surface expression, we found that bupropion and ibogaine increased DAT surface expression, whereas others, including cocaine and methylphenidate, had no effect.	Ibogaine	125-133	solute carrier family 6 member 3	Homo sapiens	73-76	
27555326-4	2016	After screening a set of known DAT ligands for their ability to increase DAT surface expression, we found that bupropion and ibogaine increased DAT surface expression, whereas others, including cocaine and methylphenidate, had no effect.	Ibogaine	125-133	solute carrier family 6 member 3	Homo sapiens	73-76	
28405636-4	2016	The folding trajectory of DAT itself is not understood, though many insights have been gained from studies of folding-deficient mutants of the closely related serotonin transporter (SERT); i.e. their functional rescue by pharmacochaperoning with (nor)ibogaine or heat-shock protein inhibitors.	Ibogaine	251-259	solute carrier family 6 member 3	Homo sapiens	26-29	
27555326-5	2016	Bupropion and ibogaine increased wild type DAT protein levels and also promoted maturation of the endoplasmic reticulum (ER)-retained DAT mutant K590A.	Ibogaine	14-22	solute carrier family 6 member 3	Homo sapiens	134-137	
27555326-7	2016	Furthermore, knockdown of coat protein complex II (COPII) component SEC24D, which is important in the ER export of wild type DAT, also blocked the rescue effects of bupropion and ibogaine.	Ibogaine	179-187	solute carrier family 6 member 3	Homo sapiens	125-128	
27555326-8	2016	These data suggest that bupropion and ibogaine promote maturation of DAT by acting as pharmacological chaperones in the ER.	Ibogaine	38-46	solute carrier family 6 member 3	Homo sapiens	69-72	
22451652-5	2012	Ibogaine noncompetitively inhibited transport by both SERT and the homologous dopamine transporter (DAT).	Ibogaine	0-8	solute carrier family 6 member 3	Homo sapiens	78-98	
22451652-5	2012	Ibogaine noncompetitively inhibited transport by both SERT and the homologous dopamine transporter (DAT).	Ibogaine	0-8	solute carrier family 6 member 3	Homo sapiens	100-103	
22451652-6	2012	Ibogaine blocked substrate-induced currents also in DAT and increased accessibility of the DAT cytoplasmic permeation pathway.	Ibogaine	0-8	solute carrier family 6 member 3	Homo sapiens	52-55	
22451652-6	2012	Ibogaine blocked substrate-induced currents also in DAT and increased accessibility of the DAT cytoplasmic permeation pathway.	Ibogaine	0-8	solute carrier family 6 member 3	Homo sapiens	91-94